Compare PNTG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | CGEN |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 143.1M |
| IPO Year | N/A | 2000 |
| Metric | PNTG | CGEN |
|---|---|---|
| Price | $29.26 | $1.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $35.33 | N/A |
| AVG Volume (30 Days) | 265.3K | ★ 411.3K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $847,274,000.00 | $6,903,000.00 |
| Revenue This Year | $36.69 | N/A |
| Revenue Next Year | $24.06 | $231.15 |
| P/E Ratio | $39.02 | ★ N/A |
| Revenue Growth | ★ 29.89 | N/A |
| 52 Week Low | $21.18 | $1.13 |
| 52 Week High | $30.46 | $2.66 |
| Indicator | PNTG | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 63.80 | 44.18 |
| Support Level | $28.47 | $1.47 |
| Resistance Level | $29.95 | $1.67 |
| Average True Range (ATR) | 0.78 | 0.09 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 39.95 | 20.01 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.